PROTAGENIC THERAPEUTICS INC (PTIX) Fundamental Analysis & Valuation

NASDAQ:PTIX • US74365N3017

Current stock price

0.74 USD
-0.56 (-43.08%)
At close:
0.43 USD
-0.31 (-41.89%)
After Hours:

This PTIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PTIX Profitability Analysis

1.1 Basic Checks

  • In the past year PTIX has reported negative net income.
  • PTIX had a negative operating cash flow in the past year.
  • In the past 5 years PTIX always reported negative net income.
  • PTIX had a negative operating cash flow in each of the past 5 years.
PTIX Yearly Net Income VS EBIT VS OCF VS FCFPTIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1M -2M -3M -4M -5M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -178.31%, PTIX is doing worse than 86.98% of the companies in the same industry.
Industry RankSector Rank
ROA -178.31%
ROE N/A
ROIC N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTIX Yearly ROA, ROE, ROICPTIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • PTIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTIX Yearly Profit, Operating, Gross MarginsPTIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PTIX Health Analysis

2.1 Basic Checks

  • PTIX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PTIX has more shares outstanding
  • There is no outstanding debt for PTIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PTIX Yearly Shares OutstandingPTIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K 500K
PTIX Yearly Total Debt VS Total AssetsPTIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • PTIX has an Altman-Z score of -9.04. This is a bad value and indicates that PTIX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.04, PTIX is doing worse than 70.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.04
ROIC/WACCN/A
WACCN/A
PTIX Yearly LT Debt VS Equity VS FCFPTIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M

2.3 Liquidity

  • A Current Ratio of 0.29 indicates that PTIX may have some problems paying its short term obligations.
  • PTIX has a Current ratio of 0.29. This is amonst the worse of the industry: PTIX underperforms 92.08% of its industry peers.
  • PTIX has a Quick Ratio of 0.29. This is a bad value and indicates that PTIX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.29, PTIX is doing worse than 91.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
PTIX Yearly Current Assets VS Current LiabilitesPTIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PTIX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.53% over the past year.
EPS 1Y (TTM)54.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTIX Yearly EPS VS EstimatesPTIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. PTIX Valuation Analysis

4.1 Price/Earnings Ratio

  • PTIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTIX Price Earnings VS Forward Price EarningsPTIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTIX Per share dataPTIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTIX Dividend Analysis

5.1 Amount

  • No dividends for PTIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTIX Fundamentals: All Metrics, Ratios and Statistics

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (1/2/2026, 8:00:01 PM)

After market: 0.43 -0.31 (-41.89%)

0.74

-0.56 (-43.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners6.08%
Inst Owner Change15.99%
Ins Owners2.86%
Ins Owner Change0%
Market Cap1.43M
Revenue(TTM)N/A
Net Income(TTM)-8.92M
Analysts82.86
Price TargetN/A
Short Float %1.32%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0
BVpS-2.44
TBVpS-3.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -178.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -9.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.09%
OCF growth 3YN/A
OCF growth 5YN/A

PROTAGENIC THERAPEUTICS INC / PTIX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PTIX.


Can you provide the valuation status for PROTAGENIC THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PROTAGENIC THERAPEUTICS INC (PTIX). This can be considered as Overvalued.


What is the profitability of PTIX stock?

PROTAGENIC THERAPEUTICS INC (PTIX) has a profitability rating of 0 / 10.


How financially healthy is PROTAGENIC THERAPEUTICS INC?

The financial health rating of PROTAGENIC THERAPEUTICS INC (PTIX) is 0 / 10.